Clinical Trials Using Gallium Ga 68-labeled PSMA-11

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gallium Ga 68-labeled PSMA-11. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • Gallium Ga 68-labeled PSMA-11 PET / MR in Diagnosing Patients with Recurrent Prostate Cancer

    This phase II trial studies how well Gallium Ga 68-labeled PSMA-11 positron emission tomography (PET) / magnetic resonance (MR) works in diagnosing patients with prostate cancer that has come back. Gallium Ga 68-labeled PSMA-11 may help to show prostate cancer on a PET / MR scan that cannot be seen on other standard imaging even when the PSA levels are very low. It may also help doctors to make decisions about the care.
    Location: 5 locations

  • 68Ga-PSMA-11 PET / CT in Diagnosing Participants with Recurrent Prostate Cancer After Radical Prostatectomy

    This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET) / computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, such as PET / CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET / CT may help doctors plan better for salvage radiation therapy in participants with recurrent prostate cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT and Fluciclovine F18 PET / CT in Imaging Participants with Recurrent Prostate Cancer after Surgery

    This phase II trial compares how well gallium 68-labeled PSMA-11 positron emission tomography / computed tomography (PET / CT) works compared to fluciclovine F18 PET / CT in imaging participants with prostate cancer after surgery that has come back. PET is an established imaging technique that uses small amounts of radioactivity and CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. Diagnostic procedures, such as PET / CT with gallium 68-labeled PSMA-11, may work better than PET / CT with fluciclovine F18 in helping find out how far the prostate cancer has spread.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients with Thyroid Cancer

    This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Participants with Biochemical Recurrent Prostate Cancer

    This phase II trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in diagnosing patients with prostate cancer and with rising prostate specific antigen after treatment. Ga-68 PSMA is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help find the presence of prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Patients with Biochemical Recurrent Prostate Cancer

    This phase II / III trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 positron emission tomography / computed tomography (PET / CT) works in diagnosing patients with biochemical recurrent prostate cancer. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help detect prostate cancer in patients with biochemical recurrent prostate cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Diagnosing Participants with Intermediate to High-Risk Prostate Cancer

    This pilot phase II / III trial studies how well gallium Ga 68-labeled PSMA-11 positron emission tomography / computed tomography (PET / CT) works in diagnosing participants with intermediate to high-risk prostate cancer. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help detect pelvic nodal disease in participants with prostate cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • 68Ga-PSMA-11 PET / CT in Imaging Patients with Intermediate or High Risk Prostate Cancer before Surgery

    This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET) / computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery. Diagnostic procedures, such as PET / CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT or PET / MRI in Diagnosing Patients with Biomedical Recurrent Prostate Cancer

    This phase III trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) or PET / magnetic resonance imaging (MRI) works in diagnosing patients with prostate cancer and with rising prostate specific antigen after treatment. Ga-68 PSMA is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT or PET / MRI, may help find the presence of prostate cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Gallium Ga 68-labeled PSMA-11 PET / MRI in Diagnosing Participants with PSMA-positive Tumors

    This pilot trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron-emission tomography (PET) / magnetic resonance imaging (MRI) works in diagnosing participants with PSMA-positive tumors. Gallium Ga 68-labeled PSMA- is an imaging drug that binds to tumor cells and can be imaged using PET / MRI. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / MRI, may help find the presence of cancer.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • 68Ga PSMA-HBED-CC PET / CT in Imaging Patients with Metastatic Prostate Cancer

    This pilot clinical trial studies how well 68Ga PSMA-HBED-CC positron emission tomography / computed tomography (PET / CT) works in imaging patients with prostate cancer that has spread to other parts of the body. Diagnostic procedures, such as 68Ga PSMA-HBED-CC PET / CT, may help find and diagnose metastatic prostate cancer and find out how far the disease has spread.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Gallium Ga 68-labeled PSMA-11 PET / CT in Detecting Recurrent Prostate Cancer in Patients after Initial Therapy

    This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) / computed tomography (CT) works in detecting prostate cancer that has come back in patients after initial therapy. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT, may help doctors detect tumors that have come back after initial therapy.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Gallium Ga 68-labeled PSMA-11 PET / CT or PET / MRI in Diagnosing Patients with Intermediate to High-Risk Prostate Cancer

    This phase I / II trial studies how well gallium Ga 68-labeled PSMA-11 positron emission tomography (PET) / computed tomography (CT) or PET / magnetic resonance imaging (MRI) work in diagnosing patients with intermediate to high-risk prostate cancer. Gallium Ga 68-labeled PSMA-11 is an imaging drug that binds to prostate tumor cells and can be imaged using PET. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET / CT and PET / MRI, may help find the presence of prostate cancer that has spread to other parts of the body.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • 68Ga-PSMA PET / MRI in Finding Tumors in Patients with Intermediate or High-Risk Prostate Cancer Undergoing Surgery

    This phase II / III trial studies gallium 68 Ga (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography / magnetic resonance imaging (PET / MRI) in finding tumors in patients with prostate cancer undergoing surgery that tend to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET / MRI, may help find and diagnose prostate cancer and find out how far the disease has spread. Radioactive drugs, such as gallium Ga 68-PSMA, binds to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • 68Ga-PSMA PET / CT in Detecting Prostate Cancer Recurrence in Patients with Elevated PSA after Initial Treatment

    This phase II / III trial studies how well gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA) positron emission tomography (PET) / computed tomography (CT) works in detecting prostate cancer that may have come back in patients with elevated prostate-specific antigen (PSA) after initial treatment. A rise in blood level of PSA, a protein made by the prostate, after treatment with surgery or radiation in patients without symptoms indicates that the cancer may have come back (recurrence). PSA however cannot determine whether the disease is located only in the prostate or other places in the body. 68Ga-PSMA is a radioactive tracer that targets and specifically binds to tumor cells expressing PSA making them lighting up. PET and CT make computerizing pictures of areas inside the body where the radioactive substance is lighting up. 68Ga-PSMA PET / CT may be able to see smaller tumors than standard imaging and may help determine whether prostate cancer has come back and where it is in the body.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California